Updates

Calnex

November 2021

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Ahead of reporting interims on 23 November, Calnex said full year profits are running “materially ahead of expectations.” All regions outside China (which is flat) have seen trading return to pre-COVID spending patterns. Factors driving recent performance include a sustained positive response to the launch of Calnex’s Lab Sync Platform, which is being adopted both by existing and new customers looking to deliver products addressing new Open Radio Access Network (O-RAN) interoperability standards, as well as increasing Sentinel uptake from hyperscale enterprise customers. Cenkos has upgraded its full year forecasts by 27% to £5.6m with that for next year lifted by 20% to £6m. Tipped at 68p in December &ls ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Alfa Financial

Luceco

Calnex (April 2023)

Calnex (December 2022)

Calnex - Strong sales momentum continues (July 2022)

Calnex (January 2022)

Calnex Solutions (September 2021)

Calnex (June 2021)

Calnex Solutions - Calnex Shares climb 143% in only two months! (January 2021)

Calnex Solutions - Neo beats expectations for 6 quarters (December 2020)

Calnex Solutions - 5G testing specialist (November 2020)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X